First Patient Dosed in Global Tumor-Agnostic Ph 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors June 3, 2024
First Patient Dosed in Randomized Ph 2 Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy May 29, 2024
First Patient Dosed in Investigator-Initiated Trial (IIT) of Danvatirsen in Ph 1 for AML/MDS Cancers May 21, 2024
RAPHAEL Registrational Ph 3 Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated R/R AML in China Initiated May 21, 2024
First Patient Dosed in Ph 1 Trial of SENTI-202 for the Treatment of R/R Hematologic Malignancies Including AML May 21, 2024
Ph 3 KeyVibe-010 Trial of Vibostolimab + Pembrolizumab coformulation as Adjuvant Treatment for Resected High-Risk Melanoma unlikely to achieve a statistically significant RFS improvement May 15, 2024
5 patients deaths reported the next day after update provided on Interim TAMARACK Ph 2 Study Data May 15, 2024
Randomized Portion (Part 2) of REFRαME-O1 Trial of luvelta for patients with platinum-resistant ovarian cancer (PROC) initiated May 7, 2024
Ph 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept + Keytruda in Patients with Untreated HPV-Mediated Oropharyngeal Cancer initiated May 7, 2024
First Patients Dosed in Two Ph 1 Trials of REM-422 of Adenoid Cystic Carcinoma (ACC) and AML/MDS May 7, 2024
First Patient Dosed in trial Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC May 7, 2024
